News
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Mar 10, 2022
Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to...
-
Mar 8, 2022
Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to...
-
Mar 2, 2022
Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to...
-
Dec 3, 2021
Creative Medical Technology Holdings, Inc. (the "Company") (NASDAQ: CELZ), a commercial stage biotechnology company focused on a regenerative approach to Immunotherapy, Urology, Neurology and...
-
Nov 9, 2021
(OTC-CELZ) Creative Medical Technology Holdings, Inc. (the "Company"), a commercial stage biotechnology company focused on immunology, urology, neurology and orthopedics using adult stem cell...
-
Oct 12, 2021Company Achieves Selective Reprogramming of Pathological Autoimmunity
(OTC-CELZ) Creative Medical Technology Holdings Inc. announced today proof of concept data demonstrating the ability of its next generation ImmCelz™ immunotherapy product to "reprogram" patient...
-
Oct 1, 2021
Creative Medical Technology Holdings Inc. (OTC – CELZ) announced today filing a new patent application covering nanoparticles called "exosomes" secreted by cells of its MyeloCelz™ platform and...
-
Sep 16, 2021
Creative Medical Technology Holdings, Inc. (OTC: CELZ), a commercial stage biotechnology company focused on a regenerative approach to Immunotherapy, Urology, Neurology and Orthopedics, today...
-
Aug 9, 2021
Creative Medical Technology Holdings, Inc. ("CELZ," the "Company", "we", "our" or "us") (OTC: CELZ) today announced that it has entered into definitive agreements with accredited institutional...
-
Jul 20, 2021Landmark Patent Containing Over 1000 Claims Filed
(OTC – CELZ) Creative Medical Technology Holdings Inc. announced today the launching of its second Regenerative Immunology product, MyeloCelz™. In contrast to the Company's ImmCelz™ product,...
-
Jun 22, 2021Courtney Bartlett DNP, ACNP-BC, RNFA to Lead Clinical Translation of Company's Regenerative Immunotherapy Pipeline
(OTC-CELZ) Creative Medical Technology Holdings announced today recruitment of Dr. Courtney Bartlett to lead clinical development of the Company's pipeline of therapeutic products. Dr. Bartlett...
-
Jun 17, 2021
Creative Medical Technology Holdings, Inc. (OTC - CELZ), announced that the company will virtually present at the Investor Forum at the World Stem Cell Summit today Thursday, June 17, 2021 at...
-
Jun 9, 2021Clinical Stage Regenerative Immunotherapy Company Optimizes Treatment for Diabetes as it Prepares for Additional Investigational New Drug Application
Creative Medical Technology Holdings, trading under Ticker Symbol CELZ, announced the filing of a provisional patent application in connection with new data indicating that the Company's ImmCelz®...
-
May 24, 2021Clinical Stage Biotechnology Company Reports Patent Filing based on Preclinical Data using "Regenerative Immunotherapy" Approach
Creative Medical Technology Holdings, trading under ticker symbol CELZ, announced today positive preclinical data supporting extension of ImmCelz® applicability to Parkinson's Disease. Using the...
-
May 20, 2021Immunologist Surgeon who Invented Islet Transplantation to Assist Company in Advancing ImmCelz® Platform
Creative Medical Technology Holdings announced today recruitment of Dr. Camillo Ricordi to the Company's Scientific Advisory Board. Dr. Ricordi will collaborate with Company Advisors such as Drs...
-
May 14, 2021FDA Responds to Creative Medical Technology Holdings Regarding Its ImmCelz® IND for Stroke TreatmentFDA Responds to Company's IND #27375 Including Pharmacology, Manufacturing and Clinical Sections
Creative Medical Technology Holdings Inc., trading under ticker symbol CELZ, announced today receipt of detailed correspondence from the FDA regarding necessary modifications to IND #27375 for...
-
Mar 23, 2021
Creative Medical Technology Holdings, Inc. (OTC: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to Immunotherapy, Urology, Neurology and Orthopedics,...
-
Mar 16, 2021
Creative Medical Technology Holdings, Inc. (OTC: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to Immunotherapy, Urology, Neurology and Orthopedics,...
-
Mar 10, 2021
Creative Medical Technology Holdings, Inc. (OTC: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to Immunotherapy, Urology, Neurology and Orthopedics,...
-
Mar 4, 2021Commercial Stage Regenerative Medicine Company Expands it's Hold "Ready to Commercialize" Autologous Bone Marrow Procedures
(OTC - CELZ) Creative Medical Technology Holdings announced today a publication in the pre-print server SSRN describing data from its first 15 patients treated in a clinical trial evaluation...
-
Mar 3, 2021
(OTC-CELZ) Creative Medical Technology Holdings announced today that due to COVID related technical changes in the FDA's submission requirements, the Company's ImmCelz® Investigational New Drug...
-
Feb 16, 2021Company Aims to Leverage Immune Modulatory Technology to Alleviate Need for Immune Suppressants after Transplantation
(OTC – CELZ) Creative Medical Technology Holdings, Inc. announced today filing of a patent application covering the use of ImmCelz® regenerative cell therapy for preventing rejection of...
-
Feb 10, 2021Company Advances Towards Clinical Trial to Address Premature Ovarian Failure Patients
(OTC-CELZ) Creative Medical Technology Holdings announced today new data explaining mechanisms of action of its patented OvaStem® female infertility/ovarian failure treatment. OvaStem®, which is...
-
Feb 8, 2021Clinical Stage Regenerative Medicine Company Plans to Develop Clinical Programs for Major Uses of ImmCelz® Regenerative Immunotherapy
(OTC-CELZ) Creative Medical Technology Holdings Inc. announced today recruitment of Dr. Caigan Du, Associate Professor at the University of British Columbia to the Company's Scientific Advisory Board.
-
Feb 1, 2021Company Demonstrates that in Addition to Activating Endogenous Stem Cells and T Regulatory Cells ImmCelz® Induces Surge of Therapeutic Protein HGF-1
(OTC – CELZ) Creative Medical Technology Holdings, Inc. announced today new data demonstrating that administration of ImmCelz® to animals with a variety of conditions results is a significant...